Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BURROUGHS WELLCOME LAUNCHING SUDAFED COLD & COUGH LIQUID CAPS

This article was originally published in The Tan Sheet

Executive Summary

BURROUGHS WELLCOME LAUNCHING SUDAFED COLD & COUGH LIQUID CAPS to the trade in July, with consumer advertising and promotion to begin in the fall. The non-drowsy, multi-symptom formula represents Burroughs Wellcome's first OTC product in a soft gel capsule. Sudafed Cold & Cough Liquid Caps will be indicated for stuffy nose, sinus congestion, minor sore throat pain, headache, body aches and pains, fever, coughing and chest congestion. The formulation includes acetaminophen 250 mg, dextromethorphan 10 mg, guaifenesin 100 mg and pseudoephedrine 30 mg. The product will be packaged in counts of 10 and 20 capsules. Media support for the product launch will include a television ad budget of $ 13 mil. with commercials scheduled to begin running in the fall. Burroughs Wellcome is telling the trade that the Sudafed Cold & Cough launch will be backed with more television ad support than any Sudafed product has ever received. New York-based McCaffrey And McCall currently handles the Sudafed line and will pick up the new line extension. Burroughs Wellcome also is increasing its advertising and promotional support for the entire Sudafed product line. The company is dedicating more than $ 28 mil. to the Sudafed brand in an advertising spree which will begin on Oct. 4. Backing the line are three nationwide free-standing inserts in Sunday newspaper supplements which will announce the introduction. Slated for Sept. 19 and January, the FSIs will include 75 " off coupon drops. An Oct. 10 FSI will feature the new product and include coupons for $ 1. Promotions also will include sample packs available in stores nationwide. In addition, the company plans to spend $ 1.7 mil. detailing the product to physicians and pharmacists. Sudafed Cold & Cough is among a slew of new line extensions based on novel OTC dosage forms (see related stories in this issue). The last time the company experimented with Sudafed dosage forms was in March 1991 following the Sudafed tampering incident in Washington state. After FDA recommended that industry move away from two-piece hard shell capsules, Burroughs Wellcome came out with Sudafed 12 Hour coated caplets.

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS081599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel